← back to search

Karla Helvie

Dana-Farber Cancer Institute · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, Cancer Treatment and Pharmacology, and Breast Cancer Treatment Studies.
h-index
15
citations
3,593
works
113
NIH funding
primary concept
Medicine
email

Recent publications

A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma
Nature Cancer 2025cited by 6position: middledoi
SlideCNA: spatial copy number alteration detection from Slide-seq-like spatial transcriptomics data
Genome biology 2025cited by 1position: middledoi
Author Correction: A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Nature Medicine 2025cited by 0position: middledoi
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Nature Medicine 2024cited by 70position: middledoi
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
Nature Communications 2024cited by 26position: middledoi
Abstract PD6-03: Spatio-molecular dissection of the breast cancer metastatic microenvironment
Cancer Research 2022cited by 1position: middledoi
Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems
Science 2021cited by 410position: middledoi
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
Cancer Discovery 2020cited by 427position: middledoi
Expansion Sequencing: Spatially Precise <i>In Situ</i> Transcriptomics in Intact Biological Systems
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 29position: middledoi
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Cancer Discovery 2018cited by 367position: middledoi
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
Nature Genetics 2018cited by 237position: middledoi
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Nature Communications 2017cited by 1,080position: middledoi
Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer
Cancer Research 2016cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nikhil Wagle · Gene Therapy Laboratory3 papers (2018–2025)Daniel L. Abravanel · Harvard University2 papers (2024–2025)Aviv Regev · Moscow Institute of Thermal Technology2 papers (2018–2025)Nancy U. Lin · San Francisco Art Institute2 papers (2018–2024)Orit Rozenblatt–Rosen · Broad Institute2 papers (2018–2025)Ofir Cohen · Broad Institute2 papers (2018–2025)Ralf Strasser · University of Regensburg1 papers (2025–2025) · 1 papers (2025–2025)Adrienne G. Waks · Harvard University1 papers (2018–2018)Johanna Klughammer · LMU Klinikum1 papers (2025–2025)Tianyu Li · Northern Jiangsu People's Hospital1 papers (2024–2024)Fei Chen · Broad Institute1 papers (2025–2025)Evan Murray · Broad Institute1 papers (2025–2025)Jorge E. Buendia-Buendia · Dana-Farber Cancer Institute1 papers (2024–2024)Jan Watter · Ludwig-Maximilians-Universität München1 papers (2025–2025)Lori Marini · Anna University, Chennai1 papers (2018–2018)Julia Waldman · Broad Institute1 papers (2025–2025)Judit Jané‐Valbuena · Broad Institute1 papers (2025–2025)Qingchun Jin · Dana-Farber Cancer Institute1 papers (2024–2024)Esha Jain · University of Georgia1 papers (2024–2024)